Neuroscientific Biopharmaceuticals Ltd (NSB) - Total Assets
Based on the latest financial reports, Neuroscientific Biopharmaceuticals Ltd (NSB) holds total assets worth AU$16.66 Million AUD (≈ $11.79 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Neuroscientific Biopharmaceuticals Ltd (NSB) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Neuroscientific Biopharmaceuticals Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Neuroscientific Biopharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. Check Neuroscientific Biopharmaceuticals Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Neuroscientific Biopharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Neuroscientific Biopharmaceuticals Ltd's total assets of AU$16.66 Million consist of 43.6% current assets and 56.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$7.27 Million | 42.8% |
| Accounts Receivable | AU$98.36K | 0.6% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$870.00 | 0.0% |
| Intangible Assets | AU$9.57 Million | 56.4% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Neuroscientific Biopharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Neuroscientific Biopharmaceuticals Ltd (NSB) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuroscientific Biopharmaceuticals Ltd's current assets represent 43.6% of total assets in 2025, a decrease from 75.7% in 2016.
- Cash Position: Cash and equivalents constituted 42.8% of total assets in 2025, up from 1.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 56.0% of total assets, an increase from 24.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 56.4% of total assets.
Neuroscientific Biopharmaceuticals Ltd Competitors by Total Assets
Key competitors of Neuroscientific Biopharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
|
Concord Biotech Limited
NSE:CONCORDBIO
|
India | Rs20.23 Billion |
|
Pharming Group NV
AS:PHARM
|
Netherlands | €473.79 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
OPTHEA LTD (SP.ADR/8)
F:UKJ2
|
Germany | €145.77 Million |
Neuroscientific Biopharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 31.62 | 179.30 | 25.02 |
| Quick Ratio | 31.62 | 179.30 | 25.02 |
| Cash Ratio | 5.33 | 172.79 | 24.04 |
| Working Capital | AU$6.37 Million | AU$4.64 Million | AU$4.98 Million |
Neuroscientific Biopharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Neuroscientific Biopharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.02 |
| Latest Market Cap to Assets Ratio | 0.86 |
| Asset Growth Rate (YoY) | 212.1% |
| Total Assets | AU$16.96 Million |
| Market Capitalization | $14.59 Million USD |
Valuation Analysis
Near Book Valuation: The market values Neuroscientific Biopharmaceuticals Ltd's assets close to their book value (0.86x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Neuroscientific Biopharmaceuticals Ltd's assets grew by 212.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuroscientific Biopharmaceuticals Ltd (2016–2025)
The table below shows the annual total assets of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$16.96 Million ≈ $12.00 Million |
+212.05% |
| 2024-06-30 | AU$5.44 Million ≈ $3.85 Million |
+2.74% |
| 2023-06-30 | AU$5.29 Million ≈ $3.74 Million |
-31.62% |
| 2022-06-30 | AU$7.74 Million ≈ $5.47 Million |
-47.82% |
| 2021-06-30 | AU$14.83 Million ≈ $10.49 Million |
+296.70% |
| 2020-06-30 | AU$3.74 Million ≈ $2.64 Million |
-27.05% |
| 2019-06-30 | AU$5.12 Million ≈ $3.63 Million |
+533.37% |
| 2018-06-30 | AU$808.90K ≈ $572.35K |
+39.72% |
| 2017-06-30 | AU$578.94K ≈ $409.64K |
+134.79% |
| 2016-06-30 | AU$246.58K ≈ $174.47K |
-- |
About Neuroscientific Biopharmaceuticals Ltd
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated … Read more